Sanofi (NYSE:SNY) Rating Lowered to Hold at StockNews.com

StockNews.com cut shares of Sanofi (NYSE:SNYGet Rating) from a buy rating to a hold rating in a research report report published on Friday morning.

Separately, UBS Group decreased their price target on shares of Sanofi from $122.00 to $121.00 and set a buy rating for the company in a research note on Friday, April 8th.

Shares of SNY stock opened at $51.01 on Friday. Sanofi has a 52 week low of $46.92 and a 52 week high of $58.10. The business’s 50 day moving average is $52.35.

Sanofi (NYSE:SNYGet Rating) last issued its quarterly earnings results on Thursday, April 28th. The company reported $1.09 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.15. The business had revenue of $10.85 billion for the quarter, compared to the consensus estimate of $10.33 billion.

Sanofi Company Profile (Get Rating)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

Featured Stories

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.